The Baltimore Orioles' recent move to re-sign Zach Eflin has sparked a wave of questions and debates among fans and analysts alike. Is this a sign of the team’s newfound depth, or a risky gamble on a player recovering from injury? Let’s dive into the details and unravel the implications of this decision.
But here's where it gets controversial: Eflin’s one-year, $10 million contract, with a mutual option for 2027, comes at a time when the Orioles have already made significant investments, most notably the $155 million deal with first baseman Pete Alonso. President of Baseball Operations and General Manager Mike Elias has been vocal about his ambitions, hinting at further high-profile acquisitions. However, Eflin doesn’t fit the mold of a top-tier starter like Framber Valdez or Ranger Suárez, whom Elias has been linked to in negotiations. So, what’s the strategy here?
Eflin, who underwent lumbar microdiscectomy in August to address chronic lower-back pain, may not even be ready for the 2025 Opening Day. This raises concerns about his immediate impact and whether the Orioles are prematurely committing resources to a player still on the mend. Elias’s focus seems to be on bolstering the rotation’s depth, providing manager Craig Albernaz with more options after a 2024 season that saw a franchise-record 70 players and 41 pitchers take the field. But is this the best use of their payroll flexibility?
And this is the part most people miss: The Orioles’ payroll is still $13 million below their 2025 total, indicating they have the financial muscle to make another splash. While they’re not spending like the Dodgers or Yankees, their recent moves signal a shift in strategy—one that prioritizes depth and resilience. Eflin’s signing is a testament to this approach, but it also begs the question: Are they spreading themselves too thin?
The roster dynamics add another layer of complexity. If Eflin starts the season on the injured list, the Orioles could field a rotation of Kyle Bradish, Trevor Rogers, Shane Baz, Dean Kremer, and Tyler Wells. Wells, a versatile pitcher who has excelled in both starting and relief roles, might be bumped to the bullpen again. But what happens when Eflin returns? The Orioles aren’t likely to adopt a six-man rotation, and Kremer, a proven workhorse who led the team in innings last season, isn’t a natural fit for the bullpen. Is it fair to relegate a reliable starter like Kremer to a relief role? Or is this a necessary sacrifice for long-term success?
The Orioles’ history of injuries adds another wrinkle. Last season, they ranked second in the American League for player games spent on the injured list. Bradish, Rogers, Baz, and Wells have all battled injuries in recent years, making Eflin’s health a critical factor. Yet, the team’s willingness to sign Alonso despite having multiple first basemen shows they’re not afraid to address needs head-on. Eflin’s signing follows this pattern, but it also raises questions about their overall strategy.
Eflin himself is determined to prove his worth. In a recent video call, he emphasized his commitment to starting, stating, ‘I plan to start. I’m a starter. I’m gonna train to show up as a starter.’ His desire for redemption after a disappointing 2024 season is palpable, but will his body cooperate? And even if it does, where does he fit in a crowded rotation?
The Orioles seem unfazed by these challenges. They’ve made it clear that there’s no such thing as ‘too much pitching,’ a myth they’re eager to debunk. Whether they sort out their roster through careful planning or rely on fate, one thing is certain: they’re playing the long game. But is this approach sustainable, or are they setting themselves up for future headaches?
As fans and analysts, we’re left with more questions than answers. Is Eflin’s signing a masterstroke of depth-building, or a risky bet on an injury-prone player? Will the Orioles’ bold strategy pay off, or will they find themselves juggling too many moving parts? Share your thoughts in the comments—let’s spark a debate!
